Attacking COVID-19 Virus Hiding in the Gastrointestinal Tract of Long-Haulers with James Sapirstein AzurRx BioPharma

James Sapirstein, President and CEO, AzurRx BioPharma, a clinical stage biopharmaceutical company specializing in therapies for gastrointestinal diseases talks about turning their focus to the virus that causes COVID-19. With a background in drug development for HIV and infectious diseases, James describes their approach to developing an oral agent targeted to COVID-19 long-haulers. AzurRx is working on an indication for COVID-19 of gastrointestinal issues that is showing that the Sars-CoV-2 virus stores itself in the reservoirs inside the human body including the gastrointestinal tract.

@azurrx #AzurRxBioPharma #COVID19 #GIDrugs #GIDiseases #COVIDLongHaulers $AZRX

AzurRx.com

Download the transcript here

Facebook
Twitter
LinkedIn
Related Post

NEWSLETTER

Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.